Skip to main content
DrugPrice

Tirosint

Levothyroxine (gel cap)

Generic availableThyroid Disordersby IBSA
$126.00
avg cost per claim
+8.6% year-over-year
$234.0M
Medicare Spending
1,860,000
Total Claims
224,000
Beneficiaries
$1,045.00
Annual Cost/Patient

Why Tirosint Costs $126.00 Per Claim

Tirosint (Levothyroxine (gel cap)) is used to treat thyroid disorders. According to CMS Medicare Part D spending data, the program spent $234.0M on this drug, covering 224,000 beneficiaries across 1,860,000 claims.

A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Levothyroxine (gel cap) or talk to their doctor about therapeutic alternatives that may cost less.

Price Breakdown

Avg cost per claim (30-day)$126.00
Avg annual cost per patient$1,045.00
Total Medicare spending$234.0M
Total claims1,860,000
Beneficiaries224,000

Drug Details

Brand Name
Tirosint
Generic Name
Levothyroxine (gel cap)
Active Ingredient
Levothyroxine (gel cap)
Manufacturer
IBSA
Dosage Form
N/A
Route
N/A
Condition
Thyroid Disorders
FDA Application
BLA125057

Frequently Asked Questions

Tirosint (Levothyroxine (gel cap)) costs an average of $126.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $1,045.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.

Tirosint averages $126.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.

A typical 30-day supply of Tirosint reflects in our Medicare Part D average of $126.00 per claim. Switching to generic Levothyroxine (gel cap) typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.

Most commercial insurance plans and Medicare Part D plans cover Tirosint, but coverage varies by formulary tier. Insurers typically prefer generic Levothyroxine (gel cap) (Tier 1, lowest copay) over brand-name Tirosint (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.

Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Levothyroxine (gel cap) is the single biggest cost reducer if your prescriber is open to it.

Brand-name Tirosint costs more than generic Levothyroxine (gel cap) primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.

Yes, a generic version of Tirosint (Levothyroxine (gel cap)) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Levothyroxine (gel cap).

Medicare Part D spent $234.0M on Tirosint, covering 224,000 beneficiaries across 1,860,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.

Ask your pharmacist about generic Levothyroxine (gel cap), which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.

For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.